Shinjiro Sato, President and CEO
Naoki Muto, Chief Accounting and Financial Officer

PLAY LIST

from the beginning

Financial Results for the Fiscal Year Ended March 31, 2022 (FY2021)
Reference
Value of the Blood and Cell Technologies Business in the Terumo Growth Strategy